2 results
Not approvedWill not start
The objective is to evaluate the efficacy and safety of two doses of masitinib (4.5 mg/kg/day and 6.0 mg/kg/day) versus matching placebo in patients diagnosed with ALS treated with Riluzole (50 mg bid).The primary objective is to demonstrate…
Approved WMORecruiting
We aim to optimize the treatment of rheumatoid arthritis patients using concentration measurements. By doing this we hope to reduce the overexposure to the drug, save costs and reduce the number of adverse events, especially infections. The goal of…